Immunic (NASDAQ:IMUX) Posts Quarterly Earnings Results, Misses Expectations By $0.20 EPS

Immunic (NASDAQ:IMUX) released its quarterly earnings results on Friday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20), FiscalAI reports.

Immunic Stock Performance

NASDAQ:IMUX traded down $0.27 during trading on Friday, reaching $7.52. The company’s stock had a trading volume of 105,145 shares, compared to its average volume of 297,743. The firm has a market cap of $102.57 million, a price-to-earnings ratio of -1.72 and a beta of 1.48. The firm has a 50 day moving average of $8.80 and a 200-day moving average of $11.51. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43.

Immunic News Summary

These are some of the IMUX news items that stood out recently:

• Positive Sentiment: The company said its pivotal ENSURE-1 and ENSURE-2 trials remain on track to report top-line results in December. It also expects its funding to last into late 2027, giving it runway beyond the upcoming readout. Article: Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
• Negative Sentiment: Third-quarter results showed a $42.3 million net loss, with a loss of $0.99 per share—worse than the $0.79 loss analysts expected. Coverage cited higher expenses and the earnings miss as reasons for investor concern. Article: Immunic Q3 loss widens on higher expenses
• Negative Sentiment: Zacks Research downgraded Immunic from “strong-buy” to “hold,” adding to near-term caution ahead of the trial results. Article: Zacks Research stock recommendations

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Roth Capital reaffirmed a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. Cantor Fitzgerald initiated coverage on Immunic in a research note on Friday, October 23rd. They set an “overweight” rating on the stock. Wedbush restated an “outperform” rating and set a $45.00 price objective on shares of Immunic in a research note on Thursday, September 10th. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Finally, Ladenburg Thalmann & Co. Inc. upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Immunic has a consensus rating of “Moderate Buy” and an average price target of $35.43.

Immunic Company Profile

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.